Exact-product label comparison
The comparison stays within the MTC and thyroid C-cell scope of each product’s boxed warning, contraindications, and section 5.1. It does not turn the label language into a claim about every thyroid condition.
| Label topic | Wegovy | Zepbound |
|---|---|---|
| Boxed warning | Semaglutide caused dose- and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures. The human relevance of these findings, and whether Wegovy causes MTC in humans, are unknown. [1] | Tirzepatide caused dose- and treatment-duration-dependent thyroid C-cell tumors in rats at clinically relevant exposures. The human relevance of these findings, and whether Zepbound causes MTC in humans, are unknown. [2] |
| Contraindication | Personal or family history of MTC, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). [1] | Personal or family history of MTC, or MEN 2. [2] |
| Symptoms named for patient counseling | Neck mass, dysphagia, dyspnea, or persistent hoarseness. [1] | Neck mass, dysphagia, dyspnea, or persistent hoarseness. [2] |
| Routine monitoring | Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection in patients treated with Wegovy. The label says this may increase unnecessary procedures because serum calcitonin has low test specificity and thyroid disease has a high background incidence. [1] | Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection in patients treated with Zepbound. The label says this may increase unnecessary procedures because serum calcitonin has low test specificity and thyroid disease has a high background incidence. [2] |
| Already-observed result or nodule | The label separately says elevated serum calcitonin, if measured, and thyroid nodules noted on physical examination or neck imaging should be further evaluated. [1] | The label separately says elevated serum calcitonin, if measured, and thyroid nodules noted on physical examination or neck imaging should be further evaluated. [2] |
Routine monitoring and evaluation of a finding are different statements
Routine monitoring
Uncertain value for early MTC detection
Both labels use this language for routine serum calcitonin monitoring or thyroid ultrasound in patients treated with the respective product. They also describe the potential for unnecessary procedures because of low calcitonin test specificity and the high background incidence of thyroid disease. [1] [2]
Finding already observed
Label says further evaluation
Both labels separately address elevated calcitonin if it has been measured, and a thyroid nodule if it has been found on examination or neck imaging. This describes the label’s response to an existing finding. It is not a screening protocol, test recommendation, diagnosis, or interpretation. [1] [2]
Safety and scope
Both labels say patients should be informed about symptoms of thyroid tumors: a mass in the neck, dysphagia, dyspnea, or persistent hoarseness. These symptoms do not diagnose MTC. This page cannot determine their cause, interpret a test or scan, choose a test, or replace a clinician’s safety instructions. [1] [2]
Boundary: this page limits its thyroid-related contraindication summary to the language in both labels: personal or family history of MTC or MEN 2. It does not generalize that language to other thyroid conditions. [1] [2]
All testing, screening, treatment, and other medical decisions remain with the prescriber and the applicable current product label.
Copy-ready prescriber-question and source-packet worksheet
Copy this as a neutral organization aid. Blank, “unknown,” “not available,” and “not measured” are valid states; do not guess. Keep original reports as the source documents.
THYROID-LABEL SOURCE PACKET Exact product name: __________________________________ / Unknown Label date shown on source: __________________________ / Unknown Personal history of MTC: _____________________________ / Unknown Family history of MTC: _______________________________ / Unknown MEN 2 history: _______________________________________ / Unknown EXISTING LAB REPORT — leave blank if none is available Test name: ___________________________________________ / Unknown Collection date: _____________________________________ / Unknown Exact value: _________________________________________ / Unknown Unit: ________________________________________________ / Unknown Printed reference range: _____________________________ / Unknown Source / laboratory: _________________________________ / Unknown Original report available separately: Yes / No / Unknown EXISTING IMAGING REPORT — leave blank if none is available Study name: __________________________________________ / Unknown Study date: __________________________________________ / Unknown Source / facility: ___________________________________ / Unknown Original report available separately: Yes / No / Unknown NEUTRAL SYMPTOM TIMING — record only what was observed Symptom in plain language: ___________________________ / Unknown First observed: ______________________________________ / Unknown Timing notes: ________________________________________ / Unknown UNANSWERED PRESCRIBER QUESTIONS 1. Which exact label version applies to the product in this record? 2. How does the label's routine-monitoring statement differ from its language about an already-observed result or nodule? 3. How does the documented personal/family MTC or MEN 2 history apply? 4. Which original lab or imaging reports should be brought separately? 5. Other question: ___________________________________ / Unknown
This worksheet is not a screening protocol, test recommendation, diagnosis, or interpretation. It preserves source details and unanswered questions for a prescriber.
Keep records in their proper place
Track injection timing and sites; keep reports separately
Jabbit supports injection scheduling, reminders, and 14-zone site rotation. Keep original lab and imaging reports separately for the prescriber.
Track injection timing in JabbitFrequently asked questions
What do the Wegovy and Zepbound labels say about routine calcitonin monitoring or thyroid ultrasound?
Each label says routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with that product. [1] [2]
What thyroid-related contraindication appears in both labels?
Both labels list a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This page does not extend that language to every thyroid condition. [1] [2]
How is an already-observed calcitonin result or thyroid nodule different?
Separately from the routine-monitoring statement, both labels say that elevated serum calcitonin, if measured, and thyroid nodules found on physical examination or neck imaging should be further evaluated. That is label language about an already-observed finding, not a routine screening protocol. [1] [2]
How should I organize injection timing, sites, and thyroid lab or imaging reports?
Jabbit supports injection scheduling, reminders, and 14-zone site rotation. Keep original lab and imaging reports separately for the prescriber.
Sources opened and checked
- [1]Wegovy US prescribing information, DailyMed: boxed warning, section 4, and section 5.1.
- [2]Zepbound US prescribing information, DailyMed: boxed warning, section 4, and section 5.1.
Both sources were opened and checked October 15, 2026.